Patent application number | Description | Published |
20080311573 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 12-18-2008 |
20080312096 | Predictive and Therapeutic Markers in Ovarian Cancer - Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described. | 12-18-2008 |
20090136961 | Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer - The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer. | 05-28-2009 |
20100003682 | Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 01-07-2010 |
20100204125 | GENETIC ALTERATIONS ASSOCIATED WITH CANCER - The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26. | 08-12-2010 |
20100291068 | NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. | 11-18-2010 |
20120141604 | NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS - The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent. | 06-07-2012 |
20130102482 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF BREAST AND OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 04-25-2013 |